Literature DB >> 21383737

B cells and macrophages in cancer: yin and yang.

Alberto Mantovani.   

Abstract

Entities:  

Mesh：

Year:  2011        PMID： 21383737     DOI： 10.1038/nm0311-285

Source DB:  PubMed          Journal:  Nat Med        ISSN： 1078-8956            Impact factor:   53.440


× No keyword cloud information.
  13 in total

Review 1.  Tumour-educated macrophages promote tumour progression and metastasis.

Authors:  Jeffrey W Pollard
Journal:  Nat Rev Cancer       Date:  2004-01       Impact factor: 60.716

Review 2.  Macrophage plasticity and interaction with lymphocyte subsets: cancer as a paradigm.

Authors:  Subhra K Biswas; Alberto Mantovani
Journal:  Nat Immunol       Date:  2010-09-20       Impact factor: 25.606

3.  B-cell-derived lymphotoxin promotes castration-resistant prostate cancer.

Authors:  Massimo Ammirante; Jun-Li Luo; Sergei Grivennikov; Sergei Nedospasov; Michael Karin
Journal:  Nature       Date:  2010-03-11       Impact factor: 49.962

4.  Macrophage polarization to a unique phenotype driven by B cells.

Authors:  Siew-Cheng Wong; Anne-Laure Puaux; Manesh Chittezhath; Irina Shalova; Tasneem S Kajiji; Xiaojie Wang; Jean-Pierre Abastado; Kong-Peng Lam; Subhra K Biswas
Journal:  Eur J Immunol       Date:  2010-08       Impact factor: 5.532

5.  Cancer-Associated Fibroblasts Are Activated in Incipient Neoplasia to Orchestrate Tumor-Promoting Inflammation in an NF-kappaB-Dependent Manner.

Authors:  Neta Erez; Morgan Truitt; Peter Olson; Sarah Tuttleton Arron; Douglas Hanahan
Journal:  Cancer Cell       Date:  2010-02-04       Impact factor: 31.743

6.  FcRgamma activation regulates inflammation-associated squamous carcinogenesis.

Authors:  Pauline Andreu; Magnus Johansson; Nesrine I Affara; Ferdinando Pucci; Tingting Tan; Simon Junankar; Lidiya Korets; Julia Lam; David Tawfik; David G DeNardo; Luigi Naldini; Karin E de Visser; Michele De Palma; Lisa M Coussens
Journal:  Cancer Cell       Date:  2010-02-04       Impact factor: 31.743

7.  The CCL3 family of chemokines and innate immunity cooperate in vivo in the eradication of an established lymphoma xenograft by rituximab.

Authors:  Elena Cittera; Marzia Leidi; Chiara Buracchi; Fabio Pasqualini; Silvano Sozzani; Annunciata Vecchi; J Douglas Waterfield; Martino Introna; Josée Golay
Journal:  J Immunol       Date:  2007-05-15       Impact factor: 5.422

8.  M2 macrophages phagocytose rituximab-opsonized leukemic targets more efficiently than m1 cells in vitro.

Authors:  Marzia Leidi; Elisa Gotti; Luca Bologna; Elena Miranda; Monica Rimoldi; Antonio Sica; Massimo Roncalli; Giuseppe A Palumbo; Martino Introna; Josée Golay
Journal:  J Immunol       Date:  2009-04-01       Impact factor: 5.422

Review 9.  Immunological and inflammatory functions of the interleukin-1 family.

Authors:  Charles A Dinarello
Journal:  Annu Rev Immunol       Date:  2009       Impact factor: 28.527

10.  Modulation of the antitumor immune response by complement.

Authors:  Maciej M Markiewski; Robert A DeAngelis; Fabian Benencia; Salome K Ricklin-Lichtsteiner; Anna Koutoulaki; Craig Gerard; George Coukos; John D Lambris
Journal:  Nat Immunol       Date:  2008-09-28       Impact factor: 25.606
View more
  21 in total

1.  CTLA4 Promotes Tyk2-STAT3-Dependent B-cell Oncogenicity.

Authors:  Andreas Herrmann; Christoph Lahtz; Toshikage Nagao; Joo Y Song; Wing C Chan; Heehyoung Lee; Chanyu Yue; Thomas Look; Ronja Mülfarth; Wenzhao Li; Kurt Jenkins; John Williams; Lihua E Budde; Stephen Forman; Larry Kwak; Thomas Blankenstein; Hua Yu
Journal:  Cancer Res       Date:  2017-07-17       Impact factor: 12.701

2.  Host antitumor resistance improved by the macrophage polarization in a chimera model of patients with HCC.

Authors:  Akira Asai; Yusuke Tsuchimoto; Hideko Ohama; Shinya Fukunishi; Yasuhiro Tsuda; Makiko Kobayashi; Kazuhide Higuchi; Fujio Suzuki
Journal:  Oncoimmunology       Date:  2017-03-03       Impact factor: 8.110

3.  Assessing the effectiveness of a Grand Rounds CME activity for health-care professionals.

Authors:  Terry Ann Glauser; P Holder Nevins; J Chad Williamson; Brian Tomlinson
Journal:  J Cancer Educ       Date:  2013-09       Impact factor: 2.037

4.  Adaptive immunity suppresses formation and progression of diethylnitrosamine-induced liver cancer.

Authors:  Carlo Schneider; Andreas Teufel; Tetyana Yevsa; Frank Staib; Anja Hohmeyer; Gudrun Walenda; Henning W Zimmermann; Mihael Vucur; Sebastian Huss; Nikolaus Gassler; Hermann E Wasmuth; Sergio A Lira; Lars Zender; Tom Luedde; Christian Trautwein; Frank Tacke
Journal:  Gut       Date:  2012-01-20       Impact factor: 23.059

5.  Tumour Microenvironment: Overview with an Emphasis on the Colorectal Liver Metastasis Pathway.

Authors:  Alexandros Giakoustidis; Satvinder Mudan; Thorsten Hagemann
Journal:  Cancer Microenviron       Date:  2014-10-03

Review 6.  The immune contexture in human tumours: impact on clinical outcome.

Authors:  Wolf Herman Fridman; Franck Pagès; Catherine Sautès-Fridman; Jérôme Galon
Journal:  Nat Rev Cancer       Date:  2012-03-15       Impact factor: 60.716

Review 7.  Immunology and immunotherapy of neuroblastoma.

Authors:  Robert C Seeger
Journal:  Semin Cancer Biol       Date:  2011-09-28       Impact factor: 15.707

8.  CD5 Binds to Interleukin-6 and Induces a Feed-Forward Loop with the Transcription Factor STAT3 in B Cells to Promote Cancer.

Authors:  Chunyan Zhang; Hong Xin; Wang Zhang; Paul J Yazaki; Zhifang Zhang; Keith Le; Wenzhao Li; Heehyoung Lee; Larry Kwak; Stephen Forman; Richard Jove; Hua Yu
Journal:  Immunity       Date:  2016-04-19       Impact factor: 31.745

9.  Extracellular NM23 Protein as a Therapeutic Target for Hematologic Malignancies.

Authors:  Junko Okabe-Kado; Takashi Kasukabe; Yasuhiko Kaneko
Journal:  Adv Hematol       Date:  2011-09-19

10.  B cells promote tumor progression via STAT3 regulated-angiogenesis.

Authors:  Chunmei Yang; Heehyoung Lee; Sumanta Pal; Veronica Jove; Jiehui Deng; Wang Zhang; Dave S B Hoon; Mark Wakabayashi; Stephen Forman; Hua Yu
Journal:  PLoS One       Date:  2013-05-29       Impact factor: 3.240
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.